Risk Factors and Progression of Keratoconus
FRPK
1 other identifier
interventional
200
1 country
1
Brief Summary
Primary objective : Description of keratoconus at baseline and during progression in 200 participants followed by the ophthalmology departments of CHU Montpellier, CHU Bordeaux and CHU Toulouse during a 2-year period. Clinical outcome, histology of the cornea and tears proteomics will be assessed in 4 groups at different points in time:
- At 6 months in participants with no intervention (risk reduction instructions: not to rub their eyes)
- At 6 months in participants with no intervention that didn't comply with the risk reduction instructions
- At 1 month in participants assigned to cross-linking surgery
- At 1 month in participants assigned to intra corneal ring surgery If both eyes are affected, both will be evaluated with their own visit agenda. Visits for no surgery participants will be set at 6 months, 12 months and 24 months in the absence of intervention (apart from the behavioral risk reduction). Visits for surgery participants will be set at D7, 1 month, 6 months, 12 months and 24 months after the procedure: cross-linking or placement of the intra corneal ring. Secondary objective : Description of the association between clinical outcomes, histological progression of the cornea and tears proteomics in time, 2 years period. Comparison of tears proteomics in 36 participants with keratoconus followed at CHU of Montpellier and healthy participants at baseline .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2022
CompletedFirst Posted
Study publicly available on registry
January 9, 2023
CompletedStudy Start
First participant enrolled
June 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2028
September 5, 2025
August 1, 2025
4 years
December 18, 2022
August 29, 2025
Conditions
Outcome Measures
Primary Outcomes (11)
Keratoconus clinical progression (Keratometry map)
Modelisation of refraction measurements in diopters, by corneal elevation topography (Orbscan and Pentacam), giving an additional indicator of the corneal deformity. High values of diopter correspond to positive bulges of the cornea. A topographic axial map will be acquired to monitor minimal and maximal keratometry. These measurements will be taken at baseline and compared for reference of progression at each visit for each eye. Keratoconus definition according to Rabinowitz (Rabinowitz YS, 1989) criteria: * Corneal asymmetry greater than 1.5 diopters (D), between the upper and lower part of the cornea, on the median vertical axis. * Central corneal power (Kmax) \> 47.2 D, measured at the top of the cone. * Asymmetry of central keratometry \> 1D between the two eyes
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus clinical progression (Pachymetric map)
Thickness of the cornea will be assessed in microns (µm) at several locations and will be presented as a map by corneal elevation topography (Orbscan and Pentacam). The pachymetric map will be acquired at baseline and compared for reference of progression at each visit for each eye. The higher and lower thickness points will be notified for the anterior and posterior parts of the eye.
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus clinical progression (Visual acuity test)
Visual acuity test with and without correction: decimal and Parinaud scales secondarily translated in LogMar.
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus clinical progression (Biomicroscopic examination of the cornea)
A biomicroscopic examination of the cornea in search of signs that may modify the therapeutic indications i.e : Fleischer rings (iron deposits in the lower part of the bulge, due to the stagnation of tears), visible corneal nerves, corneal opacities (due to scar tissue)
Baseline vs Visit at 1 month/6 months/12 months/24 months
ABCD grading of keratoconus
Grading of the keratoconus, according to the ABCD classification : * A: keratometry of the anterior surface of the cornea (Anterior radius of curvature (ARC)), in the area of 3 mm centered by the thinnest point. * B: keratometry of the posterior surface of the cornea (Back or posterior radius of curvature PRC), in the 3mm area centered by the thinnest point. * C: thinnest point of the Cornea, i.e. minimum pachymetry. * D: Distance best corrected vision: visual acuity with the best correction, measured in 10° or in the Parinaud scale.
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus histological progression - Confocal microscopy (tissue thickness)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Tissue thickness in microns (µm)
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus histological progression - Confocal microscopy (Cellular organization)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cell organization and morphology. Image acquisition. * Colonization by inflammatory cells (yes/no), increased nucleo/cytoplasmic ratio (yes/no), hyperreflectivity of the nuclei (yes/no). * Nerve density of the basal plexuses of normal appearance (yes/no), straight with branches (yes/no), normal hyperreflectivity (yes/no)
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus histological progression - Confocal microscopy (Cellular density)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cellular density (number). Image acquisition. \- Cell count in the different layers, corneal nerve count from the basal plexus to the corneal apex
Baseline vs Visit at 1 month/6 months/12 months/24 months
Keratoconus histological progression - Confocal microscopy (Light scattering)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Light scattering in vivo, measurement of corneal deformity. Diopter.
Baseline vs Visit at 1 month/6 months/12 months/24 months
Risk factors - Questionnaire
* Presence of atopy/allergy * Eye rubbing * Family medical history * Ethnicity * Smoking habits * Dry eye syndrome
Baseline vs 24 months
Tears proteomics
For 36 participants from Montpellier. Composition and evolution of tears determined by proteomic analysis
Baseline vs Visit at 1 month/6 months
Secondary Outcomes (3)
ABCD class worsening between consultations
Baseline vs Visit at 1 month/6 months - Baseline vs 12 months - Baseline vs 24 months
Keratoconus histological evolution
Baseline vs Visit at 1 month/6 months
Proteomic profile evolution
Baseline vs Visit at 1 month/6 months
Study Arms (2)
Abstention
OTHERAfter keratoconus diagnosis the patient won't be assigned to intervention
Intervention (cross-linking surgery or intra corneal ring)
OTHERAfter keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery
Interventions
After keratoconus diagnosis the patient was assigned to surgery
Eligibility Criteria
You may qualify if:
- Participants with clinical keratoconus (Rabinowitz criteria with topographic slit lamp abnormalities and visual impairment), preclinical or crude keratoconus (abnormal or suspicious topography with normal slit lamp examination and normal visual acuity, visual acuity)
- Followed by the ophthalmology services of the CHU Montpellier, CHU Bordeaux or CHU Toulouse
- For adult Participants: collection of written informed consent, after a period of reflection period
- For minors: informed consent signed by at least one of the 2 parents or legal representatives legal representatives, and assent of the child after a period of reflection
- Affiliation to the French social security system or beneficiary of such a system
You may not qualify if:
- Person under legal supervision, guardianship or curator
- History of corneal implant on both eyes
- Planned relocation before the end of the first stage of treatment (abstention, cross-linking, intra-corneal ring depending on the participant)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Gui de Chauliac - Service d'Ophtamologie
Montpellier, Occitanie, 34295, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vincent DAIEN, PR
CHU Monptellier
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 18, 2022
First Posted
January 9, 2023
Study Start
June 5, 2023
Primary Completion (Estimated)
June 5, 2027
Study Completion (Estimated)
May 1, 2028
Last Updated
September 5, 2025
Record last verified: 2025-08